Dianthus Therapeutics, Inc. (NASDAQ:DNTH) Given Consensus Recommendation of “Moderate Buy” by Brokerages

Shares of Dianthus Therapeutics, Inc. (NASDAQ:DNTH) have been given a consensus recommendation of “Moderate Buy” by the fourteen ratings firms that are currently covering the stock, MarketBeat reports. One investment analyst has rated the stock with a sell rating, twelve have assigned a buy rating and one has issued a strong buy rating on the company. The average 1 year target price among analysts that have issued a report on the stock in the last year is $117.8182.

Several research firms have recently issued reports on DNTH. Truist Financial raised their target price on shares of Dianthus Therapeutics from $63.00 to $110.00 and gave the stock a “buy” rating in a report on Monday, March 9th. Raymond James Financial reiterated a “strong-buy” rating on shares of Dianthus Therapeutics in a report on Wednesday, June 10th. Wall Street Zen raised Dianthus Therapeutics from a “sell” rating to a “hold” rating in a research report on Saturday, May 9th. William Blair restated an “outperform” rating on shares of Dianthus Therapeutics in a report on Monday, March 16th. Finally, Robert W. Baird boosted their target price on Dianthus Therapeutics from $67.00 to $132.00 and gave the stock an “outperform” rating in a research note on Tuesday, March 10th.

Insiders Place Their Bets

In other Dianthus Therapeutics news, SVP Adam M. Veness sold 30,000 shares of Dianthus Therapeutics stock in a transaction dated Wednesday, June 17th. The stock was sold at an average price of $80.80, for a total transaction of $2,424,000.00. Following the completion of the sale, the senior vice president owned 30,000 shares of the company’s stock, valued at approximately $2,424,000. The trade was a 50.00% decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, EVP Simrat Randhawa sold 26,530 shares of Dianthus Therapeutics stock in a transaction dated Monday, June 1st. The stock was sold at an average price of $90.62, for a total value of $2,404,148.60. Following the sale, the executive vice president directly owned 4,000 shares of the company’s stock, valued at $362,480. This trade represents a 86.90% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last quarter, insiders have sold 64,754 shares of company stock valued at $5,566,993. Insiders own 3.02% of the company’s stock.

Hedge Funds Weigh In On Dianthus Therapeutics

Several institutional investors and hedge funds have recently modified their holdings of DNTH. First Horizon Corp acquired a new position in shares of Dianthus Therapeutics in the 1st quarter valued at $32,000. Caitong International Asset Management Co. Ltd acquired a new position in shares of Dianthus Therapeutics during the fourth quarter valued at approximately $40,000. Raymond James Financial Inc. acquired a new position in shares of Dianthus Therapeutics during the second quarter valued at approximately $27,000. Russell Investments Group Ltd. purchased a new position in shares of Dianthus Therapeutics in the third quarter worth about $64,000. Finally, ABS Direct Equity Fund LLC purchased a new position in shares of Dianthus Therapeutics in the first quarter worth about $179,000. Institutional investors and hedge funds own 47.53% of the company’s stock.

Dianthus Therapeutics Stock Performance

Shares of DNTH opened at $95.68 on Tuesday. The company’s fifty day moving average is $86.51 and its 200 day moving average is $68.56. Dianthus Therapeutics has a fifty-two week low of $17.27 and a fifty-two week high of $97.38. The stock has a market capitalization of $5.23 billion, a PE ratio of -23.17 and a beta of 1.18.

Dianthus Therapeutics (NASDAQ:DNTH) last issued its quarterly earnings data on Tuesday, May 5th. The company reported ($0.85) earnings per share for the quarter, topping the consensus estimate of ($1.07) by $0.22. Dianthus Therapeutics had a negative return on equity of 27.30% and a negative net margin of 12,998.50%.The company had revenue of $0.46 million for the quarter, compared to analysts’ expectations of $0.40 million. As a group, research analysts forecast that Dianthus Therapeutics will post -3.82 earnings per share for the current year.

Dianthus Therapeutics Company Profile

Dianthus Therapeutics, Inc, a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy. Dianthus Therapeutics, Inc was founded in 2019 and is headquartered in New York, New York.